出海机会来了!寻找PCSK9小分子抑制剂产品,全球权益,目前所处阶段不限。请感兴趣的公司立即联系:药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共:2000字预计阅读时间:6分钟2026年开年,一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露,默沙东拟以300亿美元收购Revolution,后者目前市值为227亿美元。...
Source Link出海机会来了!寻找PCSK9小分子抑制剂产品,全球权益,目前所处阶段不限。请感兴趣的公司立即联系:药时代BD团队BD@drugtimes.cn药物开发中杂质鉴定与结构解析的案例研究 | 博腾·药时代直播间正文共:2000字预计阅读时间:6分钟2026年开年,一场超级并购传闻点燃了全球生物医药界。据英国《金融时报》媒体透露,默沙东拟以300亿美元收购Revolution,后者目前市值为227亿美元。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.